The Heartbreak of Drug Pricing
Authors: Frank Davidoff
Journal: Annals of Internal Medicine (2001)

Editorials5 June 2001The Heartbreak of Drug PricingFrank Davidoff, MD, EditorFrank Davidoff, MD, EditorDr. Davidoff: American College of Physicians–American Society for Internal Medicine, 190 N. Independence Mall West, Philadelphia, PA 19106.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-11-200106050-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail It can hardly be a mystery why the price of prescription drugs in the United States has become such a contentious issue (1). The figures speak for themselves. The average price of drugs per prescription among older persons rose 48% between 1992 and 2000, and drug expenses now consume 14% of the average Social Security benefit, up from 8% in 1992. The prescription drug costs incurred by some 850 000 older Americans who lack insurance that covers drugs are more than $2000 per year (2). The increased cost of prescription drugs accounted for the largest share—44%—of the total increase in ...References1. Angell M. The pharmaceutical industry—to whom is it accountable? [Editorial]. N Engl J Med. 2000;342:1902-4. [PMID: 10861327] CrossrefMedlineGoogle Scholar2. . Drug-price program notes. Wall Street Journal. 2000;8 August:A18. Google Scholar3. Charatan F. US doctors' incomes fell in 1999. BMJ. 2000;321:1309. [PMID: 11090509] CrossrefMedlineGoogle Scholar4. Noonan D, Raymond J, Gesalman AB. Why drugs cost so much. Newsweek. 2000;25 September:22-30. Google Scholar5. Jenkins HW. Lazy insurers hitch a ride on the drug wars. Wall Street Journal. 2000;9 August:A23. Google Scholar6. Goldman L, Cook EF. The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med. 1984;101:825-36. [PMID: 6388454] LinkGoogle Scholar7. Welch CE, Rodkey GV, von Ryll Gryska P. A thousand operations for ulcer disease. Ann Surg. 1986;204:454-67. [PMID: 3767481] CrossrefMedlineGoogle Scholar8. Xia Z, Roberts RO, Schottenfeld D, Lieber MM, Jacobsen SJ. Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States: 1980 to 1994. Urology. 1999;53:1154-9. [PMID: 10367845] CrossrefMedlineGoogle Scholar9. Chapman RH, Stone PW, Sandberg EA, Bell CC, Neumann PJ. A comprehensive league table of cost–utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making. 2000;20:451-67. [PMID: 11059478] CrossrefMedlineGoogle Scholar10. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff Millwood. 2000;19:92-109. [PMID: 10718025] CrossrefMedlineGoogle Scholar11. Witcher SK. In the land down under, a model for national drug insurance. Australia's tough approach wins attention of countries trying to lower spending. Wall Street Journal. 2000;31 August:B1. Google Scholar12. Beeley N, Berger A. A revolution in drug discovery. Combinatorial chemistry still needs logic to drive science forward [Editorial]. BMJ. 2000;321:581-2. [PMID: 10977816] CrossrefMedlineGoogle Scholar13. Horrobin DF. Innovation in the pharmaceutical industry. J R Soc Med. 2000;93:341-5. [PMID: 10928019] CrossrefMedlineGoogle Scholar14. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405:857-65. [PMID: 10866212] CrossrefMedlineGoogle Scholar15. Lahana R. How many leads from HTS? Drug Discovery Today. 1999;4:447-8. CrossrefMedlineGoogle Scholar16. Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N Engl J Med. 2000;343:141-4. [PMID: 10891526] CrossrefMedlineGoogle Scholar17. . The human genome, in proportion [Editorial]. Lancet. 2001;357:489. [PMID: 11229660] CrossrefMedlineGoogle Scholar18. Reinhardt UE. How to lower the cost of drugs. New York Times. 2001;2 January:A19. Google Scholar19. Calfee JE. Pharmaceutical price controls and patient welfare. Ann Intern Med. 2001;134:1060-4. LinkGoogle Scholar20. Jackson DZ. Drug price cuts won't kill industry. Boston Globe. 2000;22 September:A27. Google Scholar Author, Article, and Disclosure InformationAffiliations: Dr. Davidoff: American College of Physicians–American Society for Internal Medicine, 190 N. Independence Mall West, Philadelphia, PA 19106.Corresponding Author: Frank Davidoff, MD, American College of Physicians–American Society for Internal Medicine, 190 N. Independence Mall West, Philadelphia, PA 19106. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPharmaceutical Price Controls and Patient Welfare John E. Calfee The Heartbreak of Drug Pricing Johnathon S. Ross The Heartbreak of Drug Pricing Wes Lisker The Heartbreak of Drug Pricing Frank Davidoff Metrics Cited byComparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug CompaniesExtraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the U.S. Pharmaceutical Industry?The Power of Pharmacological Sciences: The Example of Proton Pump InhibitorsPharmacogenetic testing: proofs of principle and pharmacoeconomic implicationsLiving in a different worldConflicts between Commercial and Scientific Interests in Pharmaceutical Advertising for Medical JournalsLow-Molecular-Weight Heparins: Are they all the Same?The Heartbreak of Drug PricingJohnathon S. Ross, MD, MPHThe Heartbreak of Drug PricingWes Lisker, MDMedicamentos y eficiencia del gastoAnticoagulation Therapy 5 June 2001Volume 134, Issue 11Page: 1068-1071KeywordsDrug pricesDrug therapyDrugsGenetic diseasesGenomicsHealth careHealth care qualityLipidsQuality adjusted life yearsSurgery ePublished: 5 June 2001 Issue Published: 5 June 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...